Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Inactivated Influenza A/H5N1 Vaccine in Healthy Elderly Adults
NCT00230750Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2005
- Primary completion
- Jan 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of inactivated influenza a vaccine A/H5N1 in Influenza A H5N1 infection (H5N1) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric Mean Titer of Neutralizing Antibodies at Day 56, Frequency of 4-fold or Greater Increase in Neutralizing Antibody Titers at Day 56 and 2 more. Started Oct 2005; status: completed.
02
Drugs
inactivated influenza a vaccine A/H5N1
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on NCT00230750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230750.